Pieris Pharmaceuticals Inc.

0.9755-0.0198-1.99%Vol 82.61K1Y Perf -69.84%
Nov 30th, 2022 16:00 DELAYED
BID0.9300 ASK1.05
Open1.00 Previous Close0.9953
Pre-Market- After-Market1.05
 - -  0.07 7.64%
Target Price
8.00 
Analyst Rating
Strong Buy 1.00
Potential %
720.09 
Finscreener Ranking
★★★★     52.45
Insiders Trans % 3/6/12 mo.
100/100/-33 
Value Ranking
★+     42.15
Insiders Value % 3/6/12 mo.
100/100/-90 
Growth Ranking
     39.18
Insiders Shares Cnt. % 3/6/12 mo.
100/100/-73 
Income Ranking
 —    -
Price Range Ratio 52W %
1.62 
Earnings Rating
Strong Buy
Market Cap72.58M 
Earnings Date
2nd Nov 2022
Alpha-0.01 Standard Deviation0.19
Beta1.09 

Today's Price Range

0.96301.02

52W Range

0.92444.08

5 Year PE Ratio Range

-6.00-7.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.45%
1 Month
-7.97%
3 Months
-31.30%
6 Months
-44.57%
1 Year
-69.84%
3 Years
-76.03%
5 Years
-83.93%
10 Years
-

TickerPriceChg.Chg.%
PIRS0.9755-0.0198-1.99
AAPL148.036.86004.86
GOOG101.456.01006.30
MSFT255.1414.81006.16
XOM111.340.80000.72
WFC47.950.38000.80
JNJ178.001.91001.08
FB196.640.99000.51
GE85.970.31000.36
JPM138.181.62001.19
 
ProfitabilityValueIndustryS&P 500US Markets
-
-130.10
-120.30
-90.60
-83.18
RevenueValueIndustryS&P 500US Markets
28.50M
0.38
-8.04
22.36
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.16-0.1318.75
Q02 2022-0.11-0.14-27.27
Q01 2022-0.12-0.0741.67
Q04 2021-0.30-0.1356.67
Q03 2021-0.24-0.240.00
Q02 2021-0.20-0.25-25.00
Q01 2021-0.17-0.0758.82
Q04 2020-0.24-0.26-8.33
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.230.00-
12/2022 FY-0.630.00-
3/2023 QR-0.16-23.08Negative
12/2023 FY-0.63-3.28Negative
Next Report Date-
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume82.61K
Shares Outstanding74.41K
Shares Float72.88M
Trades Count293
Dollar Volume81.47K
Avg. Volume203.94K
Avg. Weekly Volume223.07K
Avg. Monthly Volume227.89K
Avg. Quarterly Volume160.86K

Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) stock closed at 0.9755 per share at the end of the most recent trading day (a -1.99% change compared to the prior day closing price) with a volume of 82.61K shares and market capitalization of 72.58M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 127 people. Pieris Pharmaceuticals Inc. CEO is Stephen S. Yoder.

The one-year performance of Pieris Pharmaceuticals Inc. stock is -69.84%, while year-to-date (YTD) performance is -74.19%. PIRS stock has a five-year performance of -83.93%. Its 52-week range is between 0.9244 and 4.0755, which gives PIRS stock a 52-week price range ratio of 1.62%

Pieris Pharmaceuticals Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 2.10, a price-to-sale (PS) ratio of 2.64, a price to cashflow ratio of 46.20, a PEG ratio of 2.32, a ROA of -26.36%, a ROC of -59.79% and a ROE of -77.45%. The company’s profit margin is -83.18%, its EBITDA margin is -120.30%, and its revenue ttm is $28.50 Million , which makes it $0.38 revenue per share.

Of the last four earnings reports from Pieris Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Pieris Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Pieris Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8, which is +720.09% compared to the current price. The earnings rating for Pieris Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Pieris Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Pieris Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.79, ATR14 : 0.07, CCI20 : -1.23, Chaikin Money Flow : -0.28, MACD : -0.02, Money Flow Index : 32.79, ROC : -1.46, RSI : 46.94, STOCH (14,3) : 53.75, STOCH RSI : 0.80, UO : 39.79, Williams %R : -46.25), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Pieris Pharmaceuticals Inc. in the last 12-months were: Tim Demuth (Buy at a value of $10 260)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.

CEO: Stephen S. Yoder

Telephone: +1 857 246-8998

Address: 255 State Street, Boston 02109, MA, US

Number of employees: 127

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

58%42%

Bearish Bullish

57%43%


News

Stocktwits